APT for HER2 breast cancer patients with small tumours

Bookmark and Share
Published: 28 Jan 2019
Views: 4728
Prof Nagi El Saghir - American University of Beirut, Beirut, Lebanon

Prof Nagi El Saghir speaks to ecancer at BGICC 2019 in Cairo about APT (adjuvant paclitaxel and trastuzumab) for HER2 small tumours.

He provides an overview of the current treatment options for varying tumour types, including support for the recent PERSEPHONE and APHINITY trials.

Prof El Saghir finishes by outlining the situation in Lebanon, and how hospitals here manage with certain limits on resources.